Jennifer X. Ji

Jennifer X. Ji

Auto-generated profile, based on publicly available information

Jennifer X. Ji

Department of Pathology and Laboratory Medicine University of British Columbia Vancouver BC Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2020 in Annual Review of Pathology: Mechanisms of Disease
Verified
Journal Article
Closed access
YWYemin Wang
Yemin Wang
LHLien Hoang
Lien Hoang
JJJennifer X. Ji
Jennifer X. Ji
DHDavid Huntsman
David Huntsman
The SWI/SNF (mating type SWItch/Sucrose NonFermentable) chromatin remodeling complexes interact with histones and transcription factors to modulate chromatin structure and control gene expression. These evolutionarily conserved multisubunit protein complexes are involved in regulating many biological functions, such as differentiation and cell proliferation. Genomic studies have revealed frequent mutations of genes encoding multiple subunits of the SWI/SNF complexes in a wide spectrum of cancer types, including gynecologic cancers. These SWI/SNF mutations occur at different stages of tumor development and are restricted to unique histologic types of gynecologic cancers. Thus, SWI/SNF mutations have to function in the appropriate tissue and cell context to promote gynecologic cancer initiation and progression. In this review, we summarize the current knowledge of SWI/SNF mutations in the development of gynecologic cancers to provide insights into both molecular pathogenesis and possible treatment implications for these diseases.

23 February 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
JJJennifer X. Ji
Jennifer X. Ji
YWYi Kan Wang
Yi Kan Wang
DCDawn R Cochrane
Dawn R Cochrane
DHDavid Huntsman
David Huntsman

16 August 2020 in Histopathology
Verified
Journal Article
Closed access
PDF file
YLYi Ariel Liu
Yi Ariel Liu
JJJennifer X Ji
Jennifer X Ji
NANoorah Almadani
Noorah Almadani
RCRichard I Crawford
Richard I Crawford
CGC Blake Gilks
C Blake Gilks
LHLynn Hoang
Lynn Hoang

14 October 2022 in The Journal of Pathology
Verified
Journal Article
Closed access
JJJennifer X Ji
Jennifer X Ji
DCDawn R Cochrane
Dawn R Cochrane
GNGian Luca Negri
Gian Luca Negri
SCShane Colborne
Shane Colborne
SMSandra E Spencer Miko
Sandra E Spencer Miko
DHDavid Huntsman
David Huntsman

3 August 2024 in The Journal of Pathology
Verified
Journal Article
Open access
JJJennifer X Ji
Jennifer X Ji
LHLien N Hoang
Lien N Hoang
DCDawn R Cochrane
Dawn R Cochrane
ALAmy Lum
Amy Lum
JSJanine Senz
Janine Senz
RGRamon Klein Geltink
Ramon Klein Geltink
Clear cell ovarian carcinoma (CCOC) is an aggressive malignancy affecting younger women. Despite ovarian cancer subtypes having diverse molecular and clinical characteristics, the mainstay of treatment for advanced stage disease remains cytotoxic chemotherapy. Late stage CCOC is resistant to conventional chemotherapy, which means a suboptimal outcome for patients affected. Despite detailed genomic, epigenomic, transcriptomic, and proteomic characterisation, subtype‐specific treatment for CCOC has shown little progress. The unique glycogen accumulation defining CCOC suggests altered metabolic pathway activity and dependency. This study presents the first metabolomic landscape of ovarian cancer subtypes, including 42 CCOC, 20 high‐grade serous and 21 endometrioid ovarian carcinomas, together comprising the three most common ovarian carcinoma subtypes. We describe a distinct metabolomic landscape of CCOC compared with other ovarian cancer subtypes, including alterations in energy utilisation and cysteine metabolism. In addition, we identify CCOC‐specific alterations in metabolic pathways including serine biosynthesis and ROS‐associated pathways that could serve as potential therapeutic targets. Our study provides the first in‐depth study into the metabolome of ovarian cancers and a rich resource to support ongoing research efforts to identify subtype‐specific therapeutic targets that could improve the dismal outcome for patients with this devastating malignancy. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

17 November 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
JJJennifer X. Ji
Jennifer X. Ji
DCDawn R Cochrane
Dawn R Cochrane
BTBasile Tessier-Cloutier
Basile Tessier-Cloutier
SCShary Chen
Shary Chen
GHGermain Ho
Germain Ho
DHDavid Huntsman
David Huntsman
Purpose: Many rare ovarian cancer subtypes such as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) have poor prognosis due to their aggressive nature and resistance to standard platinum and taxane based chemotherapy. The development of effective therapeutics has been hindered by the rarity of such tumors. We sought to identify targetable vulnerabilities in rare ovarian cancer subtypes. Experimental Design: We compared the global proteomic landscape of six cases each of endometrioid ovarian cancer (ENOC), clear cell ovarian cancer (CCOC), and SCCOHT to the most common subtype high grade serous ovarian cancer (HGSC) to identify potential therapeutic targets. Immunohistochemistry of tissue microarrays were used as validation of ASS1 deficiency. The efficacy of arginine-depriving therapeutic ADI-PEG20 was assessed in vitro using cell lines and patient derived xenograft mouse models representing SCCOHT. Results: Global proteomic analysis identified low ASS1 expression in ENOC, CCOC, and SCCOHT compared to HGSC. Low ASS1 levels were validated through IHC in a large patient cohort. The lowest levels of ASS1 were observed in SCCOHT, where ASS1 was absent in 2/15 cases, and expressed in less than 5% of the tumor cells in 8/15 cases. ASS1 deficient ovarian cancer cells were sensitive to ADI-PEG20 treatment regardless of subtype in vitro . Furthermore, in two cell line mouse xenograft models and one patient derived mouse xenograft model of SCCOHT, once a week treatment of ADI-PEG20 (30mg/kg and 15mg/kg) inhibited tumor growth in vivo . Conclusions: Preclinical in vitro and in vivo studies identified ADI-PEG20 as a potential therapy for patients with rare ovarian cancers including SCCOHT. Translational relevance: Many rare ovarian cancers lack effective management strategies and are resistant to the standard platinum- and taxane-based chemotherapy. Thus, for a rare ovarian cancer subtype like small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) - an aggressive malignancy affecting young women in their twenties, effective targeted therapeutics are urgently needed. We used global proteomics to identify a deficiency in arginosuccinate synthase (ASS1) as a common feature among some rare ovarian cancer subtypes. Using in-vitro and in-vivo models, we demonstrated that the arginine-depriving investigational agent ADI-PEG20 effectively inhibited cell growth in ASS1 deficient ovarian cancers including SCCOHT, establishing it as a potential therapeutic agent for rare ovarian cancer subtypes deficient in ASS1. Further clinical investigation is warranted.